Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Lacour is active.

Publication


Featured researches published by J. Lacour.


The New England Journal of Medicine | 1977

Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs

Umberto Veronesi; Jerzy Adamus; D. C. Bandiera; I. O. Brennhovd; E. Caceres; Natale Cascinelli; F. Claudio; R. L. Ikonopisov; V. V. Javorskj; S. Kirov; A. Kulakowski; J. Lacour; Ferdy Lejeune; Z. Mechl; Alberto Morabito; I. Rodé; S. Sergeev; E.A. van Slooten; K. Szczygiel; N. N. Trapeznikov; R. I. Wagner

From September, 1967, to January, 1974, a clinical trial was carried out by the WHO Melanoma Group to evaluate the efficacy of elective lymph-node dissection in the treatment of malignant melanoma of the extremities with clinically uninvolved regional lymph nodes. Treatment was prospectively randomized: 267 patients to excision of primary melanoma and immediate regional-lymph-node dissection and 286 to excision of primary melanoma and regional-lymph-node dissection at the time of appearance of metastases. The statistical analysis showed no difference in survival between the two groups of patients, regardless of how the data were analyzed (according to sex, site of origin, maximum diameter of primary tumor or Clarks level or Breslows thickness). Elective lymph-node dissection in malignant malanoma of the limbs does not improve the prognosis and is not recommended when patients can be followed at intervals of three months.


Radiotherapy and Oncology | 1989

Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer

D. Sarrazin; Monique G. Lê; R. Arriagada; G. Contesso; Fontaine F; Marc Spielmann; F. Rochard; Th. Le Chevalier; J. Lacour

A randomized trial was conducted at the Institut Gustave-Roussy (IGR) between 1972 and 1980 comparing tumorectomy and breast irradiation with modified radical mastectomy. One hundred and seventy-nine patients with an infiltrating breast carcinoma up to 20 mm in diameter at macroscopic examination were included: 88 had conservative management, and 91 a mastectomy. All patients had a low-axillary dissection with immediate histological examination. For the patients with positive axillary nodes, a complete axillary dissection was undertaken. Overall survival, distant metastasis, contralateral breast cancer and locoregional recurrence rates were not significantly different between the two treatment groups.


Cancer | 1982

Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities

Umberto Veronesi; Jerzy Adamus; D. C. Bandiera; I. O. Brennhovd; E. Caceres; Natale Cascinelli; F. Claudio; R. L. Ikonopisov; V. V. Javorski; S. Kirov; A. Kulakowski; J. Lacour; F. Lejeune; Z. Mechl; Alberto Morabito; I. Rodé; S. Sergeev; E. van Slooten; K. Szczygiel; N. N. Trapeznikov; R. I. Wagner

Results of a prospective randomized clinical trial conducted by the WHO Collaborating Centers for the Evaluation of Methods of Diagnosis and Treatment of Melanoma are reported. Five‐hundred‐fifty‐three Stage I patients whose limbs were affected entered the study; 267 were submitted to wide excision and immediate node dissection and 286 had wide excision and node dissection at the time clinically positive nodes were detected. Survival curves of the two treatment groups could be superimposed. No subsets of patients benefitted from immediate node dissection. The authors conclude that delayed node dissection is as effective as the immediate dissection in Stage I melanoma of the extremities if the patient can be checked every three months. If the quarterly follow‐up is not guaranteed, immediate node dissection is advisable, at least for melanomas thicker than 2 mm.


The New England Journal of Medicine | 1988

Thin Stage I Primary Cutaneous Malignant Melanoma

Umberto Veronesi; Natale Cascinelli; Jerzy Adamus; Charles M. Balch; Dino Bandiera; A. Barchuk; Rosaria Bufalino; Peter Craig; Jaime de Marsillac; J. Durand; A.N. van Geel; Hans Holmström; Ole G. Jorgensen; Bela Kiss; B. B. R. Kroon; E.A. van Slooten; J. Lacour; Ferdy Lejeune; Rona MacKie; Zdenek Mechl; G. Mitrov; Alberto Morabito; Henryk Nosek; R. Panizzon; M. Prade; Pierluigi Santi; Radmilo Tomin; Nikolaj Trapeznikov; Tsanko Tsanov; Marshall M. Urist

Although wide surgical excision is the accepted treatment for thin malignant melanomas, there is reason to believe that narrower margins may be adequate. We conducted a randomized prospective study to assess the efficacy of narrow excision (excision with 1-cm margins) for primary melanomas no thicker than 2 mm. Narrow excision was performed in 305 patients, and wide excision (margins of 3 cm or more) was performed in 307 patients. The major prognostic criteria were well balanced in the two groups. The mean thickness of melanomas was 0.99 mm in the narrow-excision group and 1.02 mm in the wide-excision group. The subsequent development of metastatic disease involving regional nodes and distant organs was not different in the two groups (4.6 and 2.3 percent, respectively, in the narrow-excision group, as compared with 6.5 and 2.6 percent in the wide-excision group). Disease-free survival rates and overall survival rates (mean follow-up period, 55 months) were also similar in the two groups. Only three patients had a local recurrence as a first relapse. All had undergone narrow excision, and each had a primary melanoma with a thickness of 1 mm or more. The absence of local recurrence in the group of patients with a primary melanoma thinner than 1 mm and the very low rate of local recurrences indicate that narrow excision is a safe and effective procedure for such patients.


Cancer | 1983

Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer

J. Lacour; Monique Le; Eduardo Caceres; Tadeus Koszarowski; Umberto Veronesi; Catherine Hill

A multicentric randomized trial evaluated the interest of internal mammary dissection on operable breast cancer patients. One thousand four hundred and fifty‐three patients were included in the study and were followed for ten years. There is no difference in survival or in relapse‐free survival between the two groups. There were significantly more local recurrences in the group without internal mammary dissection, but these recurrences occurred mainly on patients who developed metastases. A great difference between centers was observed in the number of nodes examined and there is therefore a difference in the prognostic value of the number of nodes invaded.


Cancer | 1976

Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five‐year results of an international cooperative study

J. Lacour; P. Bucalossi; E. Cacers; G. Jacobelli; T. Koszarowski; Monique Le; C. Rumeau-Rouquette; Umberto Veronesi

From 1963 to 1968, the international group collected 1580 cases of breast cancer, randomized into two therapeutic groups: radical mastectomy and extended mastectomy. The data were processed on the UNIVAC 1107 computer of the I.N.S.E.R.M. Computing Center. No significant difference was observed between the two groups in the overall five‐year survival rate. However, a more detailed analysis, according to certain prognostic features, showed that extended mastectomy improved the results in one subgroup: cancers of inner or medial quadrants, axillary N+. Within this group the difference was highly significant for a smaller subgroup (190 patients) including only tumors T1 and T2. In conclusion, there is no indication for extended mastectomy in any cancers of the outer quadrants or in those of the inner or medial quadrants without axillary involvement. A limited indication for extended mastectomy may be provisionally retained for T1 and T2 cancers of the inner or medial quadrants with axillary involvement.


Radiotherapy and Oncology | 1988

Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes

R. Arriagada; Monique G. Lê; H. Mouriesse; Fontaine F; John A. Dewar; F. Rochard; Marc Spielmann; J. Lacour; M. Tubiana; D. Sarrazin

A multivariate analysis on 1195 patients with operable breast cancer and histologically positive axillary nodes treated by mastectomy and complete axillary dissection at the Institut Gustave-Roussy between 1958 and 1978 suggests a beneficial effect of treatment of the internal mammary chain (IMC) on the risks of death and distant metastasis for the patients with medial tumors. For these patients, surgical IMC dissection and post-operative irradiation have similar effects on both the risk of death and of distant metastasis. For the patients with lateral tumors, no beneficial effect of the treatment of the IMC on these two risks was observed. Postoperative irradiation to the IMC, axilla, chest wall and supraclavicular nodes significantly decreases the risk of locoregional recurrences independent of the tumor site and surgical management of the lymph nodes.


Cancer | 1990

Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes

Monique G. Lě; R. Arriagada; Florent de Vathaire; John A. Dewar; Fontaine F; J. Lacour; G. Contesso; M. Tubiana

The effect of internal mammary chain treatment on each type of malignant deathrelated event was analyzed in 1195 patients with operable breast cancer and histologically involved axillary lymph nodes. A group of 135 patients who had no internal mammary chain treatment was compared with a control group of 1060 patients who were treated by surgery and/or postoperative radiation therapy. in a multivariate analysis taking into account age, clinical size of the tumor, histoprognostic grading, and the number of positive axillary lymph nodes, quantitative interaction tests were used to determine whether the effects of internal mammary chain treatment on each type of malignant event were significantly different for patients with a lateral tumor compared with those with a medial tumor. the authors found that the effects of this treatment on the risks of distant metastases and of secondary breast cancer were not the same for the patients with a medial tumor as for those with a lateral tumor. For the untreated patients with a medial tumor, the risks of distant metastases and second breast cancer were, respectively, 1.6 (P = 0.02) and 2.9 (P = 0.02), compared with the treated patients. Conversely, for women with lateral tumor, no difference between the two treatment groups was observed. Thus, internal mammary chain treatment may improve longterm survival rate in patients with a medial tumor and positive axillary lymph nodes essentially by decreasing the risk of development of distant metastases (mainly brain, distant lymph nodes, multiple simultaneous metastases) and/or a secondary breast cancer.


International Journal of Radiation Oncology Biology Physics | 1983

Medullary thyroid carcinoma: Prognostic factors and treatment

Philippe Rougier; C. Parmentier; Agnès Laplanche; Martine Lefevre; Jean-Paul Travagli; Bernard Caillou; Martin Schlumberger; J. Lacour; M. Tubiana

Seventy-five patients with medullary thyroid carcinoma (MTC) have been treated at Institut Gustave-Roussy from 1932 to 1979. Of these, 13 patients had distant metastases and received palliative treatment, their median survival was 3 years. Sixty-two patients with MTC limited to the neck received curative treatment; 6 had exclusive external radiotherapy for inoperable disease and 56 were surgically treated: 23 by total thyroidectomy and 33 by partial thyroidectomy. After surgery 29 patients received external radiotherapy for cervical lymph node involvement (25/29) and/or incomplete surgical resection (12/27). The survival rate was 69% at 5 years and 48% at 10 years. It was lower in patients with distant metastases at presentation (p less than 10(-5)), with tumoral infiltration of the posterior tissue planes (p less than 0.025) and in patients in whom surgical excision had not been satisfactory (p less than 0.01). It was not correlated with cervical lymph node involvement probably because those patients with lymph node involvement had been irradiated. The 29 patients who received post-operative cervical radiotherapy had initially more extensive local disease (p less than 0.05) than the 27 patients treated by surgery alone, nevertheless their survival was slightly higher. No difference in survival rate was observed between patients treated by total thyroidectomy or partial thyroidectomy, among whom only 4 local recurrences occurred. Three of the 6 patients treated with external radiotherapy alone experienced long survival (4, 7 and 10 years) and a fourth is still in clinical remission 4 years after treatment. The effectiveness of chemotherapy in patients with metastases was poor, only one patient out of 6 had a partial remission following a treatment by adriamycin. In the familial form and multiple endocrine neoplasia type II, total thyroidectomy appears to be indicated. In the sporadic cases, partial thyroidectomy is usually sufficient. External radiotherapy is effective in MTC and seems to be able to eradicate small foci of residual tumor; it is indicated when surgical excision is impossible or incomplete.


Tumori | 1980

Stage I melanoma of the limbs. Immediate versus delayed node dissection

Umberto Veronesi; Jerzy Adamus; D. C. Bandiera; I. O. Brennhovd; E. Caceres; Natale Cascinelli; F. Claudio; R. L. Ikonopisov; V. V. Javorskj; S. Kirov; A. Kulakowski; J. Lacour; Ferdy Lejeune; Z. Mechl; Alberto Morabito; I. Rodé; S. Sergeev; E. van Slooten; K. Szczygiel; N. N. Trapeznikov; R. I. Wagner

553 patients with stage I malignant melanoma of the limbs entered a prospective randomized clinical trial carried out by the W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma from September 1967 to January 1974. 286 patients were submitted to wide excision of primary and node dissection at the time as appearance of regional lymph node metastases and 267 to wide excision and immediate node dissection. Survival was identical in the 2 groups. Different subsets of patients were evaluated to assess whether some groups of patients may benefit from immediate node dissection. As regards sex, females and a significantly higher survival rate than males (p < 0.05), but results were not improved by immediate node dissection. Maximum diameter and elevation of primary melanoma were significantly related to survival but also in these cases immediate node dissection did not achieve better results. 63 patients had an excisional biopsy of their melanoma within 4 weeks before final treatment. This procedure did not worsen survival and also in this case immediate node dissection did not improve survival. 273 cases were classified according to histologic type: survival of superficial spreading and nodular melanoma was not different at a statistically significant level after the 2 treatment modalities. 325 cases were considered classifiable according to Clarks levels, out of these 165 were submitted to immediate node dissection. Neither level III nor level IV cases showed higher survival rate after immediate node dissection. Maximum tumor thickness according to Breslow was evaluated in 338 cases: 188 were submitted to wide excision and immediate node dissection. In no clusters of thickness did the enlarged surgical procedure achieve better results. The authors conclude that there is good evidence that in stage I melanoma of the extremities delayed dissection is as effective as the immediate one in the control of the disease if the patient can be kept under strict clinical control. Immediate node dissection is advisable if the quarterly follow-up is not guaranteed, at least for melanomas thicker than 2 mm.

Collaboration


Dive into the J. Lacour's collaboration.

Top Co-Authors

Avatar

Fanny Lacour

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

A. Spira

French Institute of Health and Medical Research

View shared research outputs
Top Co-Authors

Avatar

D. Sarrazin

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

Umberto Veronesi

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

G. Contesso

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

G. Delage

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

M. Tubiana

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Natale Cascinelli

American Society of Clinical Oncology

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge